Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Labeled, Propective, Multicentric Phase IV Study to Examine the Influence of Pharmacogenetic Markers on the Efficacy and Side Effects in Postmenopausal, Steroid Hormone Positive Breast Cancer Patients, Who Are Treated With Letrozol.

NCT01908556 is registered in ClinicalTrials.gov with Institut fuer Frauengesundheit as lead sponsor.

NCT NCT01908556
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01908556 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Labeled, Propective, Multicentric Phase IV Study to Examine the Influence of Pharmacogenetic Markers on the Efficacy and Side Effects in Postmenopausal, Steroid Hormone Positive Breast Cancer Patients, Who Are Treated With Letrozol.
Lead sponsor
Institut fuer Frauengesundheit
Phase
Phase 4
Overall status
Unknown status
Start date
February 28, 2009
Completion date
Not reported
Enrollment
3,545 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

is to identify biomarkers that could predict the efficacy of an adjuvant letrozol treatment in postmenopausal breast cancer patients.